Dawnrays Pharmaceutical (Holdings) Limited

SEHK:2348 株式レポート

時価総額：HK$1.8b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Dawnrays Pharmaceutical (Holdings) マネジメント

マネジメント 基準チェック /34

Dawnrays Pharmaceutical (Holdings)'sの CEO はWeixian Wuで、 Feb2022年に任命され、 の在任期間は 2.33年です。 の年間総報酬はCN¥ 3.34Mで、 65%給与と35%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.13%を直接所有しており、その価値はHK$ 2.34M 。経営陣と取締役会の平均在任期間はそれぞれ17.8年と16.1年です。

主要情報

Weixian Wu

最高経営責任者

CN¥3.3m

報酬総額

CEO給与比率65.0%
CEO在任期間2.3yrs
CEOの所有権0.1%
経営陣の平均在職期間17.8yrs
取締役会の平均在任期間16.1yrs

経営陣の近況

Recent updates

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

May 25
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Apr 22
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Apr 08
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Mar 25
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Aug 30
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

May 26
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Apr 04
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Sep 19
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Sep 22
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals

Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Sep 12
Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015

Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Aug 29
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015

Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Feb 28
Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend

Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Feb 07
Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?

Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Jan 14
Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares

Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Dec 22
Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Dec 09
What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?

Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

Nov 23
Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend

CEO報酬分析

Dawnrays Pharmaceutical (Holdings) の収益と比較して、Weixian Wu の報酬はどのように変化したか？
日付総報酬給与会社業績
Dec 31 2023CN¥3mCN¥2m

CN¥326m

Sep 30 2023n/an/a

CN¥384m

Jun 30 2023n/an/a

CN¥442m

Mar 31 2023n/an/a

CN¥400m

Dec 31 2022CN¥3mCN¥2m

CN¥358m

報酬と市場: Weixianの 総報酬 ($USD 460.19K ) は、 Hong Kong市場 ($USD 351.54K ) の同規模の企業の平均を上回っています。

報酬と収益: Weixianの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Weixian Wu (55 yo)

2.3yrs

在職期間

CN¥3,339,000

報酬

Mr. Weixian Wu serves as Chief Executive Officer of Dawnrays Pharmaceutical (Holdings) Limited since February 16, 2022. He joined Nanjing PharmaRays Science and Technology Co., Ltd., a non-wholly owned sub...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Kei Ling Li
Co-Founder & Executive Chairman21.7yrsCN¥1.05m7.16%
CN¥ 126.7m
Weixian Wu
Chief Executive Officer2.3yrsCN¥3.34m0.13%
CN¥ 2.4m
Yung Lai Hung
Co-Founder & Executive Director29.4yrsCN¥672.00k0.13%
CN¥ 2.2m
Yi Jun Wu
Chief Financial Officer6.2yrsデータなしデータなし
Kit Ling Pang
Company Secretaryno dataデータなしデータなし

17.8yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: 2348の経営陣は経験豊富で経験豊富です（平均在職期間は17.8年）。

取締役

名称ポジション在職期間報酬所有権
Kei Ling Li
Co-Founder & Executive Chairman21.7yrsCN¥1.05m7.16%
CN¥ 126.7m
Yung Lai Hung
Co-Founder & Executive Director21.7yrsCN¥672.00k0.13%
CN¥ 2.2m
Hao Xi Ede
Independent Non-Executive Director9yrsCN¥326.00kデータなし
Hong Man Leung
Non-Executive Director18.6yrsCN¥271.00kデータなし
Tung Sing Lo
Independent Non-Executive Director13.7yrsCN¥326.00kデータなし
Ming Yee Lam
Independent Non-Executive Director6.1yrsCN¥326.00kデータなし

16.1yrs

平均在職期間

60.5yo

平均年齢

経験豊富なボード: 2348の 取締役会 は経験豊富で 経験豊富 です ( 16.1年の平均在任期間)。